Science & Technology
New approach for immune modulation against T1D
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44DK135218-01A1
Award Ceiling
$1.5M
Award Floor
$1.5M
Close Date
Aug 31, 2025
Total Funding
$1.5M
Expected Awards
1
Posted Date
Sep 20, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R44DK135218-01A1
Description
SBIR Phase Phase II award: "New approach for immune modulation against T1D" awarded to EVOQ THERAPEUTICS, INC. in ANN ARBOR, Michigan. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,518,300. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.